Million BazillionBack to BusinessI've Always Wondered ...Econ Extra Credit with David BrancaccioMake Me Smart Daily

Loading...

0:00
0% played
Marketplace has a new podcast for kids, "Million Bazillion!" EPISODE OUT NOW
Stories Tagged as

FDA

Who will end up paying the price for Biogen's new Alzheimer's drug?

by Kimberly Adams
Jun 18, 2021
The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.
Biogen’s new Alzheimer's treatment drug, Aduhelm, has an annual sticker price of $56,000.
Dominick Reuter/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

Australian company first to develop fully at-home COVID test

by Victoria Craig
Dec 17, 2020
Everything needed for the test — which the FDA gave emergency authorization — is inside the box, except for a smartphone.
The Ellume COVID-19 Home Test connects directly to users’ smartphone, providing for step-by-step instructions and display of test results.
Ellume Health
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

Moderna asking U.S., European regulators to OK vaccine

by Associated Press
Nov 30, 2020
Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December.
Joel Saget/AFP via Getty Images
Share Now on:
SHARE
COVID-19

Pfizer to ask today for emergency vaccine authorization

by David Brancaccio , Jasmine Garsd and Alex Schroeder
Nov 20, 2020
Emergency authorization means the FDA facilitates availability of the vaccine during a declared state of emergency.
An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes with the logo of pharmaceutical company Pfizer, on Nov. 17, 2020.
Justin Tallis/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

FDA issues alert about accuracy of Abbott rapid COVID-19 test

by David Brancaccio , Nova Safo and Alex Schroeder
May 15, 2020
The concern is that it could be returning false negative results.
For now, negative results from the Abbott test should be confirmed with another more sensitive test.
Win McNamee/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
EEC: Econ 101

In the COVID-19 economy, unintended consequences play a part in policymaking

by David Brancaccio and Erika Soderstrom
Apr 23, 2020
A rise in domestic violence, a decline in car accidents and more.
FDA deregulation of COVID-19 antibody tests has led to a false sense of security for some, an unintended consequence of the move.
Al Bello/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE

The search for tastier grocery store tomatoes is closing in

by Sabri Ben-Achour
Nov 22, 2019
While identifying lost flavor genes and bringing them back has been tricky, some scientists are determined.
The flavor of tomatoes is hard to track, unlike disease.
Scott Olson/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE

The future is bright … let’s make it even brighter together.

Be a Marketplace Investor with a donation in any amount today.

Invest in marketplace

Energy drinks may cause serious heart problems, study shows

by Renata Sago
May 30, 2019
A combination of ingredients may cause potentially life-threatening electrical malfunctions in the heart.
Jack Taylor/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE

New gene therapy drug expected to hit market with head-spinning price tag

by Kimberly Adams
May 22, 2019
Industry analysts expect the price for the single-treatment therapy to be anywhere from $1.5 million to $5 million.
Swiss pharmaceutical giant Novartis' Basel headquarters.
SEBASTIEN BOZON/AFP/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Government shutdown 2019

Tech IPOs were set for a comeback, then the government shut down

by Molly Wood
Jan 18, 2019
Is the tech IPO resurgence at risk?
Companies like Uber that have filed for IPOs are stalled while the SEC lawyers and accountants who work on IPOs are shut down along with the government.
Adam Berry/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE